Mutation burden determines
sensitivity to PD1 blockade in NSCLC
*Partial or stable response lasting >6 months.
Months
100
50
0
4
8
12
16
20
24
High nonsynonymous burden (n=17)
Low nonsynonymous burden (n=17)
Percent Progression-Free
HR 0.19, 95% CI 0.08-0.47, log-rank
P
=0.0004
Durable
clinical benefit*
(n=14)
No durable
Benefit
(n=17)
Number of nonsynonymous mutations/tumor
299
127
Rizvi N, et al. Science. 2015;348(6230):124-128.
